Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 12/2017

01.08.2017 | Adis Drug Evaluation

Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes

verfasst von: Lesley J. Scott

Erschienen in: Drugs | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Subcutaneous insulin glargine/lixisenatide (Suliqua™) is a titratable, fixed-ratio combination of a long-acting basal insulin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of adult patients with inadequately controlled type 2 diabetes. Once-daily insulin glargine/lixisenatide, in combination with metformin, provided effective glycaemic control and was generally well tolerated in the 30-week, multinational, phase 3 LixiLan-O and LixiLan-L trials in insulin-naive and -experienced adult patients with inadequately controlled type 2 diabetes. Although long-term clinical experience with this fixed-ratio combination is currently lacking, given its convenient once-daily regimen and beneficial effects on glycaemic control and bodyweight loss in the absence of an increase in the incidence of hypoglycaemia, insulin glargine/lixisenatide is an emerging option for the treatment of adult patients with type 2 diabetes to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another OAD or basal insulin.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64–71.CrossRef
3.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.CrossRefPubMed
4.
5.
Milligan S. Combination therapy for improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: rationale and evidence for early initiation. J Diabetes Complicat. 2016;30:1177–85.CrossRefPubMed
6.
Wilding JPH, Bain SC. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in type 2 diabetes, with special reference to IDegLira. Diabet Med. 2016;33(7):864–76.CrossRefPubMed
7.
Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabet Obes Metabol. 2016;18(3):203–16.CrossRef
8.
9.
Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–34.CrossRef
10.
European Medicines Agency. Suliqua 100 units/mL + 50 micrograms/mL solution in a prefilled pen, Suliqua 100 units/mL + 33 micrograms/mL solution in a prefilled pen: summary of product characteristics. 2017. http://​www.​ema.​europa.​eu. Accessed 8 Mar 2017.
11.
Sanofi-aventis US LLC. Soliqua™ 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use: US prescribing information. 2016. http://​www.​fda.​gov/​. Accessed 14 Mar 2017.
12.
Blair H, Keating GM. Insulin glargine 300 U/mL: a review in diabetes mellitus. Drugs. 2016;76:363–74.CrossRefPubMed
13.
Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63(16):1743–78.CrossRefPubMed
14.
Scott LJ. Lixisenatide: a review of its use in patients with type 2 diabetes mellitus. BioDrugs. 2013;27(5):509–23.CrossRefPubMed
15.
Lorenz M, Pfeffer C, Steinsträßer A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes: relationship to postprandial glycemia. Regul Pept. 2013;185:1–8.CrossRefPubMed
16.
Meier JJ, Menge B, Schenker N, et al. Mechanisms of action of the glucose-lowering effect of lixisenatide in combination with insulin glargine [abstract no. 281-OR]. Diabetes. 2015;64(Suppl 1):A74.
17.
Kovatchev B, Umpierrez G, Renard E. The differential and combined action of insulin glargine and lixisenatide on the fasting and post-prandial components of glucose control [abstract no. 3]. Diabetologia. 2016;59(Suppl 1):S2.
18.
Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–35.CrossRefPubMed
19.
Rosenstock J, Diamant M, Aroda VR, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial. Diabetes Care. 2016;39(9):1579–86.CrossRefPubMed
20.
Davies M, Russell-Jones D, Barber TM, et al. iGlarLixi fixed-ratio combination in patients with HbA1c ≥9%: LixiLan-O subgroup analysis [abstract]. 2017. In: 77th ADA Meeting; 2017.
21.
Handelsman Y, Chovanes C, Dex T, et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination in elderly patients with T2D [abstract no. 954-P]. Diabetes. 2016;65(Suppl 1):A246.
22.
Davis M, Leiter LA, Grunberger G, et al. Impact of baseline HbA1c, BMI, and diabetes duration on the efficacy and safety of LixiLan (insulin glargine/lixisenatide titratable fixed-ratio combination) vs. insulin glargine and lixisenatide in the LixiLan-O trial [abstract no. 1028-P]. Diabetes. 2016;65(Suppl 1):A268.
23.
Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39(11):1972–80.CrossRefPubMed
24.
Wysham C, Bonadonna RC, Aroda V, et al. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. Diabetes Obes Metab. 2017. doi:10.​1111/​dom.​12961.
25.
Ritzel R, Vidal J, Aroda VR, et al. Efficacy and safety across the final dose ranges in patients with T2DM receiving insulin glargine/lixisenatide fixed-ratio combination in the LixiLan-L trial [abstract no. 1024-P]. Diabetes. 2016;65(Suppl 1):A266–7.
26.
ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.CrossRef
27.
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.CrossRefPubMed
28.
29.
Levin PA. Practical combination therapy based on pathophysiology of type 2 diabetes. Diabetes Metabol Syndr Obesity Targets Ther. 2016;9:355–69.CrossRef
30.
Greig SL, Scott LJ. Insulin degludec/liraglutide: a review in type 2 diabetes. Drugs. 2015;75(13):1523–34.CrossRefPubMed
31.
European Medicines Agency. Xultophy 100 units/mL + 3.6 mg/mL liraglutide solution for injection: summary of product characteristics. 2014. http://​www.​ema.​europa.​eu. Accessed 21 March 2017.
32.
Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161–72.CrossRefPubMed
33.
Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine. Diabetes Care. 2013;36(9):2497–503.CrossRefPubMedPubMedCentral
34.
Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin. Diabetes Care. 2013;36(9):2489–96.CrossRefPubMedPubMedCentral
35.
Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910–7.CrossRefPubMedPubMedCentral
36.
Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. Diabetes Care. 2016;39(8):1318–28.CrossRefPubMed
37.
Eto K, Naito Y, Seino Y. Evaluation of efficacy and safety of lixisentide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials. Diabetol Metab Syndr. 2015;7:106.CrossRefPubMedPubMedCentral
38.
Zannad F, Stough WG, Lipicky RJ, et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk asessment vs. risk aversion. Eur Heart J. 2016;2:200–5.
39.
European Medicines Agency. Guidelines on clinical investiagtion of medicinal products in the treatment or prevention of diabetes mellitus. 2012. http://​www.​ema.​europa.​eu. Accessed 22 Mar 2017.
Metadaten
Titel
Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes
verfasst von
Lesley J. Scott
Publikationsdatum
01.08.2017
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 12/2017
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0783-4

Weitere Artikel der Ausgabe 12/2017

Drugs 12/2017 Zur Ausgabe

Original Research Article

Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System

Review Article

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies

Leading Article

Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives

AdisInsight Report

Durvalumab: First Global Approval

AdisInsight Report

Abaloparatide: First Global Approval

Review Article

Therapeutic Utility of Opioids for Restless Legs Syndrome